195
Participants
Start Date
September 20, 2024
Primary Completion Date
June 8, 2026
Study Completion Date
June 8, 2026
REGN9933
Intravenous (IV) single dose administered
REGN7508
IV single dose administered
Placebo
IV single dose administered
RECRUITING
Sveta Sofia Hospital, Sofia
RECRUITING
Mount Sinai Medical Center, New York
RECRUITING
Memorial Sloan Kettering, New York
RECRUITING
Sylvester Comprehensive Cancer Center, Miami
RECRUITING
Henry Ford Health System, Detroit
RECRUITING
Rabin Medical Center, Petah Tikva
RECRUITING
Tel Aviv Sourasky Medical Center, Tel Aviv
RECRUITING
Soroka University Medical Center, Beersheba
RECRUITING
Hadassah University Medical Center, Jerusalem
RECRUITING
Arensia Exploratory Medicine Clinic at Country Hospital Cluj-Napoca, Cluj-Napoca
RECRUITING
Lanadio Medical Center, Netanya
RECRUITING
Sheba Medical Center, Ramat Gan
RECRUITING
Shaare Zedek Medical Center, Jerusalem
RECRUITING
Brigham and Women's Hospital, Boston
RECRUITING
London Health Sciences Centre, London
RECRUITING
Lakeridge Health, Oshawa
RECRUITING
University Health Network, Toronto
RECRUITING
University hospital Southampton, Southampton
RECRUITING
Cardiff and Vale University Health Board - University Hospital Wales, Cardiff
RECRUITING
The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne
Regeneron Pharmaceuticals
INDUSTRY